CelgeneBUE:CELG 10 Days Payable is 186.39 as of Sep. 2019, which is 2% above its 10-year median of 182.58. GuruFocus rates BUE:CELG with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.
Celgene's average Accounts Payable for the
three
months ended in Sep. 2019 was ARS19,077.44 Mil. Celgene's Cost of Goods Sold for the
three
months ended in Sep. 2019 was ARS9,339.64 Mil.
Hence, Celgene's Days Payable for the
three
months ended in Sep. 2019 was 186.39.
The historical rank and industry rank for Celgene's Days Payable or its related term are showing as below:
BUE:CELG'
s Days Payable Range Over the Past 10 Years
Min: 61.81 Med: 182.58 Max: 259.91
Current: 245.08
During the past 13 years, Celgene's highest Days Payable was 259.91. The lowest was 61.81. And the median was 182.58.
BUE:CELG's Days Payable is not ranked
in the Drug Manufacturers industry.
Industry Median: 90.38
vs BUE:CELG: 245.08
Celgene's Days Payable
increased
from Sep. 2018 (142.76) to Sep. 2019 (186.39).
It may suggest that Celgenedelayed paying its suppliers.
Celgene Days Payable Related Terms
Celgene Days Payable Historical Data
* Premium members only.
The historical data trend for Celgene's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUE:CELG vs GILD, BIIB, ACT: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Celgene's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celgene Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celgene's Days Payable distribution charts can be found below:
* The bar in red indicates where Celgene's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Celgene's Days Payable for the fiscal year that ended in Dec. 2018 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celgene (BUE:CELG) has a Days Payable of 186.39 as of Sep. 2019. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Celgene and its competitors. This is near median its historical median of 182.58. Over the past decade, Celgene's Days Payable has ranged from 61.81 to 259.91.
Is Celgene's Days Payable too high?
Celgene's current Days Payable of 186.39 is near median its 10-year median of 182.58. Over the past 10 years, this metric has ranged from a low of 61.81 to a high of 259.91. The Drug Manufacturers industry median Days Payable is 90.38. Celgene's value of 186.39 is 106.2% above this industry median. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Celgene's Days Payable compare to GILD and BIIB?
Celgene's Days Payable of 186.39 can be compared against companies in the Drug Manufacturers industry. The industry median Days Payable is 90.38. Celgene's value of 186.39 is 106.2% above this benchmark. Historically, Celgene's own Days Payable has ranged from 61.81 to 259.91 over the past decade. While the company's 10-year median is 182.58 vs. the industry median of 90.38, Celgene has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celgene's current Days Payable of 186.39 is 106.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Celgene and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celgene's current Days Payable is 186.39, which is near median its own 10-year median of 182.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celgene stock overvalued right now?
Celgene (BUE:CELG) has a current Days Payable of 186.39. The current Days Payable is 186.39, which is near median its 10-year median of 182.58 and 106.2% above the Drug Manufacturers industry median of 90.38. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Celgene (BUE:CELG), the current Days Payable is 186.39 as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:CELG has been successfully added to your 